Abstract
An asymmetric synthesis of the C1 to C11 and C14 to C18 fragments of the macrocyclic portion of the antibiotic Leucascandrolide A was achieved in 21 total steps from an achiral dienoate. The key 4-hydroxy-2,5-pyran portion of the natural product was established by oxy-Michael cyclization of a 5,7,9,11-tetraol intermediate, which in turn was established by an iterative asymmetric-hydration of dienoates. Alternative strategies for establishing the polyol stereochemistry were explored.
Graphical Abstract

An iterative asymmetric hydration of dienoates approach to Leucasndrolide A was explored.
Introduction
As part of humankind’s continuous search for unique biologically active structures from the deep blue sea, Leucascandrolide A (1) was discovered in the Coral Sea off the northeastern coast of New Caledonia.1 In 1996, Pietra reported the isolation of the macrocyclic lactone from the calcareous sponge Leucascandra caveolata. A combination of 2D-NMR and Mosher ester analysis was used to assign the absolute and relative stereochemistry of the macrocyclic natural product. In addition to its novel structure, interest in Leucascandrolide A was further peaked by discovery that it possessed potent anticancer and antifungal activity, with IC50 value against the human KB (70 nM) and P388 (350 nM) cell lines and activity against Candida albicans.1 As is often the problem associated with marine natural products isolated from sponges, as opposed to the bacteria that most likely produce it, Leucascandrolide A no longer appears to be available from the same sponge.2 These factors have inspired synthetic organic chemist to pursue the total synthesis of Leucascandrolide A.
A mere four years after its isolation, the first total synthesis of Leucascandrolide A was completed by Leighton.3 Since the Leighton synthesis there have been 10 other total4 and 11 formal syntheses.5 More recently, Kozmin was able to show that Leucascandrolide A inhibits oxidative phosphorylation via interaction with cytochrome bc1 complex.6 As part of a larger program aimed at the synthesis and SAR-study of anticancer agents that act by inhibition of ion transport, we became interested in the synthesis of Leucascandrolide A.
Retrosynthetically, we envisioned that the Leucascandrolide A macrocycle (1) could be derived by ring closing cross metathesis and reductive cyclization of diene 2 (Scheme 1). Compound 2 in turn could be derived from an anti-selective crotylation of aldehyde 3 Aldehyde 3 could be prepared by an esterification of alcohol 4 and acid 5 Carboxylic acid 5 could be derived from protected tetraol 6 which could result from a diastereoselective allylation/cross metathesis of protected trihydroxy ester 7.7 Previously we have shown that esters such as 7 can be derived by the iterative asymmetric hydration of dienoates like 8.8 The β-hydroxy enone 4 was also envisioned as ultimately arising from an asymmetric hydration of a dienoate. Herein we describe our latest efforts aimed at the synthesis of the C1 to C11 and C14 to C18 containing fragment of Leucascandrolide A, aldehyde 3.
Scheme 1.
Retrosynthesis of Leucascandrolide A
Results and discussion
Our synthetic efforts aimed at Leucascandrolide A began with aldehyde 9 (Scheme 2), which we previously had shown could be made from the DibalH reduction of esters like 7.9 Exposure of aldehyde 9 to the vinylogous Horner-Wadsworth-Emmons reagent 10 and LiOH as base gave the desired dienoate 11 (68%),10 which could be converted into the desired syn/anti-1,3,5-triol by our three step asymmetric hydration protocol. Thus, treating the E,E-dienoate 11 to the typical Sharpless asymmetric dihydroxylation conditions (5% OsO4, 6% (DHQ)2PHAL, K3FeCN6, MeSO2NH2), provided diol 12 in good yield (71%) and as a single diastereomer.11 Exposing diol 12 to a pyridine solution of triphosgene converted it into a cyclic carbonate 13 in good yield (79%). When cyclic carbonate 13 was exposed to our Pd-reduction conditions (HCO2H/Et3N, 1% Pd2(dba)3•CHCl3/5% PPh3) it cleanly reacted to give the 5-hydroxy-1-enoate anti-14a in an excellent yield (79%).
Scheme 2.
Os/Pd approach to protected triol
Following a nearly identical procedure, we previously have shown that anti-14b with a C11 PMB-group, can be prepared from a dienoate like 8 (P3 = PMB).8 Similarly, the C5 diastereomer syn-14b was also prepared from the same dienoate, by simply replacing the ligand in the Sharpless dihydroxylation to (DHQD)2PHAL.
To our surprise, we found it difficult to protect the C5 alcohol of anti-14a with either a TBDPS-group or a benzyl-group (Table 1). The benzyl protection was similarly problematic, whether acidic or basic conditions were used. In contrast, we were able to react alcohol anti-14b with MOMCl to give MOM-ether anti-15e in a satisfactory yield (47%). To our delight, the C5 diastereomer syn-14e reacted under a similar procedure to give syn-15e in a similar yield (52%).
Table 1.
Screening of protection groups on δ-hydroxyl enoate
| ||||
|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (anti-15) |
| 1a | anti-14a | TBS | TBDPS | NRe (anti-15a) |
| 2b | anti-14a | TBS | Bn | low (anti-15b) |
| 3c | anti-14b | PMB | Bn | low (anti-15c) |
| 4d | anti-14b | PMB | MOM | 47% (anti-15d) |
| ||||
|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (syn-15) |
| 5d | syn-14b | PMB | MOM | 52% (syn-15e) |
Reaction conditions:
TBDPSCl (2 equiv), imidazole (2.5 equiv), DMF, 18h;
benzyl trichloroacetimidate (1.2 equiv), TMSOTf, CH2Cl2;
BnBr (2 equiv), NaH, TBAI, THF, 24h;
MOMCl (4 equiv), DMAP (3% equiv), i-Pr2NEt, CH2Cl2, 0 °C;
NR = no reaction.
We surmised that the difficulty associated with the protection of the C5 hydroxyl group could be due to the acidity of the C4 position and the propensity of the substrate to undergo elimination to form dienoates 11 Thus we decided to explore an alternative procedure (Scheme 3) for the synthesis of enoates, like syn-15 Specifically, we decided to pursue a route where the protection step occurred before the ester group was introduced. This revised route was envisioned to occur through an allylation, protection and cross-metathesis sequence.
Scheme 3.
Alternative synthesis of protected triol
The revised route began with the unselective allylation of aldehyde 9 with an allylic Grignard reagent (AllylMgCl). The Grignard addition occurred to give a mixture of diastereomeric homo-allylic alcohols syn-16a and anti-16a (1.2:1), which could be separated by silica gel chromatography. Fortunately, the diastereoselectivity for the formation of syn-16a could be improved by an oxidation/reduction sequence (Scheme 3).
Thus, the mixture of alcohols syn/anti-16a was treated with the Dess-Martin reagent to give β,γ-unsaturated enone 17 in good yield (88%). Then reduction of enone 17 with L-selectride occurred to give the syn-16a as the major isomer. When the reaction was performed at −90 °C the maximal syn/anti ratio was achieved (>4:1).
To our delight we were able to protect both homo-allylic alcohols syn-16a and anti-16a with both the TBDPS and Bn- ether groups, as well as the MOM-group (Table 2). While the yields for the benzyl protection of either the syn- or anti-homoallylic alcohols were suboptimal, both TBDPS- and MOM-groups could be installed in excellent yields (78–87%), providing ample quantities syn-18a and syn-18b and anti-18a and anti-18b to pursue the cross metathesis protocol (Table 3).
Table 2.
Screening of protection groups on homoallyic alcohol
| ||||
|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (syn-18) |
| 1a | syn-16a | TBS | TBDPS | 83% (syn-18a) |
| 2b | syn-16a | TBS | Bn | 48% (syn-18b) |
| 3c | syn-16b | PMB | Bn | 49% (syn-18c) |
| 4d | syn-16b | PMB | MOM | 87% (syn-18d) |
| ||||
|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (anti-18) |
| 5a | anti-16a | TBS | TBDPS | 78% (anti-18a) |
| 6b | anti-16b | PMB | Bn | 52% (anti-18c) |
| 7d | anti-16b | PMB | MOM | 85% (anti-18d) |
Reaction conditions:
TBDPSCl (2 equiv), imidazole (2.5 equiv), DMF, 18h;
benzyl trichloroacetimidate (1.2 equiv), TMSOTf, CH2Cl2;
BnBr (2 equiv), NaH, TBAI, THF, 24h;
MOMCl (4 equiv), DMAP (3% equiv), i-Pr2NEt, CH2Cl2, 0 °C.
Table 3.
Alternative route to diol 19
| |||||
|---|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (syn-15) |
Yield (syn-19) |
| 1 | syn-16b | TBS | Bn | 96% (syn-15b) | NAc (syn-19b) |
| 2 | syn-16c | PMB | Bn | 91% (syn-15c) | 72% (syn-19c) |
| 3 | syn-16d | PMB | MOM | 90% (syn-15d) | 80% (syn-19d) |
| |||||
|---|---|---|---|---|---|
| Entry | SM | R1 | R2 | Yield (anti-15) |
Yield (anti-19) |
| 4 | anti-16e | TBS | TBDPS | 88% (anti-15e) | low (anti-19e) |
| 5 | anti-16g | PMB | MOM | 92% (anti-15g) | 71% (anti-19g) |
Reaction conditions:
ethyl acrylate (2.5 equiv), Grubbs II catalyst (1.5% equiv), CH2Cl2, reflux, 4h;
80% acetic acid/H2O, 60 °C, 4h;
not attempted.
With an improved procedure for installing protecting groups at the C5 position in syn-/anti-18 we next investigated the cross metathesis of syn-18 and anti-18 to form syn-15 and anti-15 and the subsequent deprotection to form diols syn-19 and anti-19 (Table 3). Treatment of syn-18b-d with ethyl acrylate and Grubbs II catalyst (1.5%) cleanly provided the desired enoates syn-15b-d in excellent yields (90–96%). Unfortunately, the primary TBS-groups were not compatible with the benzylidene deprotection conditions, whereas the PMB-group survived. The deprotection of the benzylidene group was accomplished by heating the enoates syn-15b/d in 80% aqueous acetic acid (60 °C) to provide the syn-diols syn-19b/d (72% and 80%). Following a similar procedure, the anti-diastereomer anti-16g was also converted into anti-19g.
We next pursued the formation of the 2,6-cis-pyran ring. This was most easily accomplished under basic conditions. The addition of 1 equiv of potassium t-butoxide to a −40 °C solution of syn-19c in THF, followed by warming to room temperature led to the formation of tetrahydropyran syn-20c (70%). Under similar condition syn-19d was converted into tetrahydropyran syn-20d (61%). These conditions produced tetrahydropyran syn-21c in 70% yield as a 6:1 ratio of cis and trans diastereomers, and tetrahydropyran syn-21d product in a 61% yield with a 7:1 ratio of cis to trans diastereomers. Formation of the methyl ether was accomplished using Me3OBF4 on syn-20c and syn-20d to produce the products syn-21c and syn-21d in excellent yields (75 and 97%, respectively). Turning to the synthesis of the C1 to C11 and the C14 to C18 portion of Leuscandrolide A, we undertook the synthesis of alcohol 24 from δ-hydroxy enoate 22 Previously we have shown that 22 can be prepared by an asymmetric hydration of the corresponding dienoate.8 The double bond of enoate 22 was oxidatively cleaved by a dihydroxylation (OsO4/NMO)/diol cleavage (NaIO4) sequence to form aldehyde 23 Addition of vinylmagnesium bromide to the aldehyde 23 and manganese dioxide oxidation of the allylic alcohol completed the synthesis of enone 24.
To demonstrate the viability of the synthesis going forward, we chose to pursue the fragment coupling sequence with ester syn-21d With the synthesis of enone 24 complete, the ester 26 was synthesized via a DCC coupling of the carboxylic acid of ester 25 and alcohol 24 The hydrolysis of ester syn-21d was accomplished by treatment with LiOH in THF and H2O. The conversion of the PMB-ether to the aldehyde began with a DDQ deprotection. Treatment of a dichloromethane solution of 26 with H2O and DDQ produced the primary alcohol 27 in 78% yield. Oxidation of the primary alcohol 27 to the aldehyde 3 was accomplished with Dess-Martin reagent.
Conclusions
In conclusion we have shown the viability of the asymmetric hydration of dienoate for the synthesis of key chiral building blocks for the synthesis of a potential Leuscandrolide A precursor 2 The further elaboration of this advanced intermediate is ongoing and will be reported in due course.
Supplementary Material
Figure 1.
Structure of Leucascandrolide A
Scheme 4.
Synthesis of tetrahydropyran
Scheme 5.
Synthesis of enone
Scheme 6.
Completion of Leucascandrolide A fragment
Acknowledgments
We are grateful to NIH (GM090259) and NSF (CHE-1565788) for financial support of this research.
Footnotes
Electronic Supplementary Information (ESI) available: See DOI: 10.1039/x0xx00000x
Notes and references
- 1.D’Ambrosio M, Guerriero A, Debitus C, Pietra F. Helv. Chim. Acta. 1996;79:51–59. [Google Scholar]
- 2.D’Ambrosio M, Tato M, Debitus C, Pietra F. Helv. Chim. Acta. 1999;82:347. [Google Scholar]
- 3.Hornberger KR, Hamblett CL, Leighton JL. J. Am. Chem. Soc. 2000;122:12894. [Google Scholar]
- 4.(a) Paterson I, Tudge M. Angew. Chem. Int. Ed. 2003;42:343. doi: 10.1002/anie.200390112. [DOI] [PubMed] [Google Scholar]; (b) Paterson I, Tudge M. Tetrahedron. 2003;59:6833. [Google Scholar]; (c) Wang Y, Janjic J, Kozmin SA. J. Am. Chem. Soc. 2002;124:13670. doi: 10.1021/ja028428g. [DOI] [PubMed] [Google Scholar]; (d) Wang Y, Janjic J, Kozmin SA. Pure Appl. Chem. 2005;77:1161. [Google Scholar]; (e) Fettes A, Carreira EM. Angew. Chem. Int. Ed. 2002;41:4098. doi: 10.1002/1521-3773(20021104)41:21<4098::AID-ANIE4098>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]; (f) Fettes A, Carreira EM. J. Org. Chem. 2003;68:9274. doi: 10.1021/jo034964v. [DOI] [PubMed] [Google Scholar]; (g) Wipf P, Reeves JT. Chem. Comm. 2002:2066. doi: 10.1039/b207383h. [DOI] [PubMed] [Google Scholar]; (h) Crimmins MT, Siliphalvanh P. Org. Lett. 2003;5:4641. doi: 10.1021/ol035797o. [DOI] [PubMed] [Google Scholar]; (i) Williams DR, Patnaik S, Plummer SV. Org. Lett. 2003;5:5035. doi: 10.1021/ol036071v. [DOI] [PubMed] [Google Scholar]; (j) Evans PA, Andrews WJ. Angew. Chem. Int. Ed. 2008;47:5426. doi: 10.1002/anie.200801357. [DOI] [PubMed] [Google Scholar]; (k) Jung HH, Seiders JR, Floreancig PE. Angew. Chem. Int. Ed. 2007;46:8464. doi: 10.1002/anie.200702999. [DOI] [PubMed] [Google Scholar]; (l) Su Q, Dakin LA, Panek JS. J. Org. Chem. 2007;72:2–24. doi: 10.1021/jo0610412. [DOI] [PubMed] [Google Scholar]; (m) Su Q, Panek JS. Angew. Chem. Int. Ed. 2005;44:1223. doi: 10.1002/anie.200462408. [DOI] [PubMed] [Google Scholar]; (n) Van Orden LJ, Patterson BD, Rychnovsky SD. J. Org. Chem. 2007;72:5784–5793. doi: 10.1021/jo070901r. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.a) Crimmins MT, Carroll CA, King BW. Org. Lett. 2000;2:597. doi: 10.1021/ol991345t. [DOI] [PubMed] [Google Scholar]; (b) Dakin LA, Langille NF, Panek JS. J. Org. Chem. 2002;67:6812. doi: 10.1021/jo0204000. [DOI] [PubMed] [Google Scholar]; (c) Dakin LA, Panek JS. Org. Lett. 2003;5:3995. doi: 10.1021/ol035581m. [DOI] [PubMed] [Google Scholar]; (d) Ferrie L, Boulard L, Pradaux F, Bouzbouz S, Reymond S, Capdevielle P, Cossy J. J. Org. Chem. 2008;73:1864. doi: 10.1021/jo701315h. [DOI] [PubMed] [Google Scholar]; (e) Ferrie L, Reymond S, Capdevielle P, Cossy J. Org. Lett. 2007;9:2461. doi: 10.1021/ol070670a. [DOI] [PubMed] [Google Scholar]; (f) Kopecky DJ, Rychnovsky SD. J. Am. Chem. Soc. 2001;123:8420. doi: 10.1021/ja011377n. [DOI] [PubMed] [Google Scholar]; (g) Kozmin SA. Org. Lett. 2001;3:755. doi: 10.1021/ol015514x. [DOI] [PubMed] [Google Scholar]; (h) Lee K, Kim H, Hong J. Org. Lett. 2011;13:2722. doi: 10.1021/ol200824r. [DOI] [PubMed] [Google Scholar]; (i) Williams DR, Plummer SV, Patnaik S. Angew. Chem. Int. Ed. 2003;42:3934. doi: 10.1002/anie.200351817. [DOI] [PubMed] [Google Scholar]; (j) Williams DR, Plummer SV, Patnaik S. Tetrahedron. 2011;67:5083. doi: 10.1016/j.tet.2011.05.020. [DOI] [PMC free article] [PubMed] [Google Scholar]; (h) Wipf P, Graham TH. J. Org. Chem. 2001;66:3242. doi: 10.1021/jo005787q. [DOI] [PubMed] [Google Scholar]; (k) Yadav JS, Pattanayak MR, Das PP, Mohapatra DK. Org. Lett. 2011;13:1710. doi: 10.1021/ol200223q. [DOI] [PubMed] [Google Scholar]
- 6.Ulanovskaya OA, Janjic J, Suzuki M, Sabharwal SS, Schumacker PT, Kron SJ, Kozmin SA. Nat. Chem. Biol. 2008;4:418–424. doi: 10.1038/nchembio.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.(a) Smith CM, O'Doherty GA. Org. Lett. 2003;5:1959–1962. doi: 10.1021/ol0345529. [DOI] [PubMed] [Google Scholar]; (b) Li M, O’Doherty GA. Org. Lett. 2006;8:6087–6090. doi: 10.1021/ol062595u. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Guo H, Mortensen MS, O’Doherty GA. Org. Lett. 2008;10:3149–3152. doi: 10.1021/ol801055b. [DOI] [PubMed] [Google Scholar]
- 8.(a) Hunter TJ, O'Doherty GA. Org. Lett. 2001;3:2777–2780. doi: 10.1021/ol016399t. [DOI] [PubMed] [Google Scholar]; (b) Hunter TJ, Wang Y, Zheng J, O’Doherty GA. Synthesis. 2016;48:1700–1710. [Google Scholar]; (c) Garaas SD, Hunter TJ, O'Doherty GA. J. Org. Chem. 2002;67:2682–2685. doi: 10.1021/jo0163400. [DOI] [PubMed] [Google Scholar]; (d) Li M, O’Doherty GA. Org. Lett. 2006;8:3987–3990. doi: 10.1021/ol061439k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.(a) Wang Y, O’Doherty GA. J. Am. Chem. Soc. 2013;135:9334–9337. doi: 10.1021/ja404401f. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Hunter TJ, O'Doherty GA. Org. Lett. 2001;3:1049–1052. doi: 10.1021/ol0156188. [DOI] [PubMed] [Google Scholar]
- 10.(a) Burden RS, Crombie L. J. Chem. Soc. C. 1969:2477. [Google Scholar]; (b) Bohlmann F, Zdero C. Chem. Ber. 1973;106:3779. doi: 10.1002/cber.19731060432. [DOI] [PubMed] [Google Scholar]; (c) Roush WR. J. Am. Chem. Soc. 1980;102:1390. [Google Scholar]; (d) Evans DA, Fitch DM. J. Org. Chem. 1997;62:454. doi: 10.1021/jo9621884. [DOI] [PubMed] [Google Scholar]; (e) Posner GH, Lee JK, White MC, Hutchings RH, Dai H, Kachinski JL, Dolan P, Kensler TW. J. Org. Chem. 1997;62:3299. doi: 10.1021/jo970049w. [DOI] [PubMed] [Google Scholar]; (f) Barrett AGM, Hamprecht D, White AJP, Williams DJ. J. Am. Chem. Soc. 1997;119:8608. [Google Scholar]; (g) Takacs JM, Jaber MR, Clement F, Walters C. J. Org. Chem. 1998;63:6757. [Google Scholar]; (h) Nazare M, Waldmann H. Chem.;Eur. J. 2001;7:3363. doi: 10.1002/1521-3765(20010803)7:15<3363::aid-chem3363>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]; (i) Sun M, Deng Y, Batyreva E, Sha W, Salomon RG. J. Org. Chem. 2002;67:3575. doi: 10.1021/jo0105383. [DOI] [PubMed] [Google Scholar]; (j) Tsuzuki T, Tanaka K, Kuwahara S, Miyazawa T. Lipids. 2005;40:147. doi: 10.1007/s11745-005-1369-1. [DOI] [PubMed] [Google Scholar]; (k) Barth R, Mulzer J. Angew. Chem. Int. Ed. 2007;46:5791. doi: 10.1002/anie.200701065. [DOI] [PubMed] [Google Scholar]; Markiewicz JT, Schauer DJ, Lofstedt J, Corden SJ, Wiest O, Helquist P. J. Org. Chem. 2010;75:2061–2064. doi: 10.1021/jo902422y. [DOI] [PubMed] [Google Scholar]
- 11.Berker H, Soler MA, Sharpless KB. Tetrahedron. 1995;51:1345.Zhang Y, O'Doherty GA. Tetrahedron. 2005;61:6337–6351. For synthetic application of this, see: Hunter TJ, O’Doherty GA. Org. Lett. 2002;4:4447–4450. doi: 10.1021/ol0269502.Xing Y, O’Doherty GA. Org. Lett. 2009;11:1107–1110. doi: 10.1021/ol9000119.Ahmed Md M, Mortensen MS, O’Doherty GA. J. Org. Chem. 2006;71:7741–7746. doi: 10.1021/jo061200h.Ahmed Md M, O’Doherty GA. Tetrahedron Lett. 2005;46:3015–3019.Ahmed Md M, Berry BP, Hunter TJ, Tomcik DJ, O’Doherty GA. Org. Lett. 2005;7:745–748. doi: 10.1021/ol050044i.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.







